221 related articles for article (PubMed ID: 37565297)
1. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19.
Ameratunga R; Mears E; Leung E; Snell R; Woon ST; Kelton W; Medlicott N; Jordan A; Abbott W; Steele R; Rolleston W; Longhurst H; Lehnert K
Clin Exp Immunol; 2023 Dec; 214(3):289-295. PubMed ID: 37565297
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
[TBL] [Abstract][Full Text] [Related]
6. Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection.
Ameratunga R; Woon ST; Steele R; Snell R; Medlicott N; Mears E; Leung E; Lehnert K; Jordan A; Das S; Abbott W; Longhurst H; Quiñones-Mateu ME
Expert Rev Clin Immunol; 2021 Jun; 17(6):553-560. PubMed ID: 33792473
[No Abstract] [Full Text] [Related]
7. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
8. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
10. An overview on the treatments and prevention against COVID-19.
Panahi Y; Gorabi AM; Talaei S; Beiraghdar F; Akbarzadeh A; Tarhriz V; Mellatyar H
Virol J; 2023 Feb; 20(1):23. PubMed ID: 36755327
[TBL] [Abstract][Full Text] [Related]
11. A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.
Chang CW; Parsi KM; Somasundaran M; Vanderleeden E; Liu P; Cruz J; Cousineau A; Finberg RW; Kurt-Jones EA
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891350
[TBL] [Abstract][Full Text] [Related]
12. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
Vanhulle E; Stroobants J; Provinciael B; Camps A; Noppen S; Maes P; Vermeire K
Antiviral Res; 2022 Jul; 203():105342. PubMed ID: 35595082
[TBL] [Abstract][Full Text] [Related]
15. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
16. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
17. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.
Beeraka NM; Sadhu SP; Madhunapantula SV; Rao Pragada R; Svistunov AA; Nikolenko VN; Mikhaleva LM; Aliev G
Front Immunol; 2020; 11():552925. PubMed ID: 33072093
[TBL] [Abstract][Full Text] [Related]
18. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).
Lee JH; Choi M; Jung Y; Lee SK; Lee CS; Kim J; Kim J; Kim NH; Kim BT; Kim HG
Biosens Bioelectron; 2021 Jan; 171():112715. PubMed ID: 33099241
[TBL] [Abstract][Full Text] [Related]
19. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
20. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Li SR; Tang ZJ; Li ZH; Liu X
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
